Molecular Partners announces its unaudited financial results for the first half-year 2018, including promising updated data on the phase 2 trial of its lead oncology asset MP0250 and the positive phase 3 topline data for abicipar, as announced on July 19, 2018 by the company’s strategic partner Allergan.

Allergan and Molecular Partners Announce Two Positive Phase 3 Clinical Trials for Abicipar pegol 8 and 12-week Regimens for the Treatment in Patients with Neovascular Age-Related Macular Degeneration

Molecular Partners announces the appointment of PamelaTrail as Chief Scientific Officer and Michael Stumpp as Chief Operating Officer of the company.

Molecular Partners presents updated preliminary results from its ongoing Phase 2 study of MP0250 at the European Hematology Association (EHA) in Stockholm.

Molecular Partners presents the complete safety and efficacy results of the Phase 1 study of its lead proprietary oncology drug MP0250 at the Annual Meeting 2018 of the American Society of Clinical Oncology (ASCO) in Chicago.

Molecular Partners announces its Interim Management Statement for the period ending March 31, 2018.

Molecular Partners presented preliminary results from the ongoing Phase 2 study of MP0250 with bortezomib and dexamethasone in patients with relapsed refractory multiple myeloma (RRMM) at the 1st European Myeloma Network Meeting in Turin.

At the AGM of Molecular Partners, the shareholders approved all motions proposed by the Board with a large majority and elected Bill Burns as new Chairman.

Molecular Partners and AstraZeneca collaborate on Molecular Partners’ ongoing phase 1b/2 clinical study of MP0250 with osimertinib (Tagrisso®) for the treatment of patients with EGFR-mutated Non-Small Cell Lung Cancer (NSCLC) pre-treated with osimertinib.

Molecular Partners presents new pre-clinical data from two of its pipeline candidates, MP0310 and MP0250, as well as the DARPin® toolbox at the AACR Annual Meeting 2018 in Chicago.